NCT05686538View on ClinicalTrials.gov

Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions
AML/MDS
Interventions
OTHER

iDLI

TCRab/CD19 depleted DLI 14 days after allogeneic stem cell transplantation. Targeted cell doses: \>10e7 NK cells/kg and \>10e6 TCRgd cells/kg

Trial Locations (1)

2100

RECRUITING

Copenhagen University Hospital, Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER